Dear Pharmaceutical Management Agency,

On 15 August 2022, Pharmac made a press release (https://pharmac.govt.nz/news-and-resourc...) on the funding application for Trikafta (elexacaftor/texacaftor/ivacaftor) stating: "We also estimate that Trikafta could give people with cystic fibrosis who are aged 6 and over a longer and improved quality of life – specifically benefits equivalent to 27 more years at full health when compared to current funded treatments." The "27 more years at full health" figure has been widely publicised by advocacy groups and the media, but I can't seem to find a source or any form of calculation on how that figure was obtained. The closest I got was from the publicly-available technology assessment report, which show an incremental QALY gain of 9.8 years, just a third of the stated 27 years.

Can you please release information of how the "27 more years at full health" figure was calcuated?

Yours faithfully,

Laydan Mortensen